Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Next Previous
Search
Trial Profile

A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Sorafenib (Primary) ; Cisplatin
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Nasopharyngeal cancer; Oropharyngeal cancer; Salivary gland cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 22 May 2018 Status changed from active, no longer recruiting to completed.
  • 01 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Dec 2017.
  • 27 Jul 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2016.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top